FCGR2A and systemic lupus erythematosus: A certain single-nucleotide polymorphism (SNP) in the FCGR gene, the FCGR3A 158V/V genotype (also called the 176V/V genotype), enhances ligation of rituximab to this receptor [8, 9], and it has been associated with improved clinical response in non-Hodgkin lymphoma and rheumatoid arthritis (RA) [10–12], as well as with B-lymphocyte depletion in patients with systemic lupus erythematosus (SLE) [13].